Hepatitis C: recent advances and practical management

R O'Kane, E Hathorn - Frontline Gastroenterology, 2023 - fg.bmj.com
Hepatitis B virus and hepatitis C virus (HCV) remain leading causes of disability and
premature death worldwide. In May 2016, the UK, as a member of the World Health …

Hepatocellular Carcinoma: The Role of Surgery in Liver Cirrhosis

DT Koch, F Horné, MP Fabritius, J Werner, M Ilmer - Visceral Medicine, 2024 - karger.com
Background: Liver surgery is an essential component of hepatocellular carcinoma (HCC)
treatment. Advances in surgical techniques and perioperative care have improved outcomes …

Comparison of different noninvasive scores for assessing hepatic fibrosis in a cohort of chronic hepatitis C patients

M El-Kassas, W Elakel, A Elsharkawy, N Asem… - Scientific Reports, 2024 - nature.com
The continuous search for simple, noninvasive methods for assessing liver fibrosis remains
very important to help risk-stratify and follow-up patients with chronic hepatitis C virus (HCV) …

Diagnostic performance of two non-invasive biomarkers used individually and in sequential combination for cirrhosis associated with hepatitis C virus infection

MAM Suan, HK Chan, X Sem, S Shilton… - Scientific Reports, 2022 - nature.com
This cross-sectional study evaluated the performance of the Aspartate Aminotransferase-to-
Platelet Ratio Index (APRI) and the Fibrosis-4 (FIB-4) Index when they were used …

The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma

H Li, C Liang, D Kuang, G Huang, M Zhang… - Cancer Biology & …, 2023 - Taylor & Francis
Objective Limited studies have reported the impact of drug-eluting bead transarterial
chemoembolization (DEB-TACE) on hepatic fibrosis in hepatocellular carcinoma (HCC) …

A nomogram model for predicting advanced liver fibrosis in patients with hepatitis B: A multicenter study

B Hu, L Yang, RB Li, J Gong, EH Dai, W Wang… - Clinica Chimica …, 2025 - Elsevier
Background Biopsy is the gold standard method for diagnosing liver fibrosis. FibroScan is a
non-invasive method of diagnosing liver fibrosis, but it still faces some limitations. This study …

Dynamic strategies and optimal control analysis for hepatitis C management: non-invasive liver fibrosis diagnosis

R Zarin, N Shukla, A Khan, J Shukla… - Computer Methods in …, 2024 - Taylor & Francis
This study proposes a novel model employing nonlinear ordinary differential equations to
dissect HCV dynamics. Six distinct population groups are delineated: Susceptible …

The Use of Noninvasive Scores in Predicting NAFLD Progression After Bariatric Surgery

L Ahmed, S Gebran, A Persaud, K Saeed, K Khan… - Obesity Surgery, 2023 - Springer
Background Bariatric surgery has been postulated to impact liver function resulting in
favorable effects on nonalcoholic fatty liver disease (NAFLD). We aimed to analyze the long …

Development of a diagnostic support system for the fibrosis of nonalcoholic fatty liver disease using artificial intelligence and deep learning

N Preechathammawong… - … Journal of Medical …, 2024 - Wiley Online Library
Liver fibrosis is a pathological condition characterized by the abnormal proliferation of liver
tissue, subsequently able to progress to cirrhosis or possibly hepatocellular carcinoma. The …

基于索磷布韦的直接抗病毒药物治疗丙型肝炎肝硬化患者疗效评价

蔡峻岭, 苏立, 郝丽, 赵敏, 裴旭东 - 实用肝脏病杂志, 2024 - manu43.magtech.com.cn
目的探讨基于索磷布韦(SOF) 的直接抗病毒药物(DAAs) 治疗代偿期丙型肝炎肝硬化(CHC-
CLC) 和失代偿期丙型肝炎肝硬化(CHC-DLC) 患者的临床疗效. 方法2019 年7 月~ 2022 年12 …